CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a developer of innovative RNA-targeted therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has notified the Company that they are continuing ... CNBC, 1 day ago
Sarepta Therapeutics Inc (SRPT) Stock Gains as Janney Capital Discusses Eteplirsen - Bidness Etc, 2 days ago
Here's Why Sarepta Therapeutics Inc (SRPT) Stock Shot up Today - Bidness Etc, 1 day ago
3 images for "pdufa"
May 17 Genmab A/S : * Pdufa target action date of September 10, 2016 for Ofatumumab * Ofatumumab in combination with fludarabine and cyclophosphamide for relapsed CLL accepted for priority review by FDA Source text for Eikon: Further company ...Reuters UK, 1 week ago Genmab - PDUFA target action date of September 10 for Ofatumumab Reuters UK, 1 week ago
By John Vandermosten, CFA NASDAQ:LPCN 1Q:16 Financial and Operational Results On May 9, 2016, Lipocine Inc. (LPCN) reported first quarter 2016 results, posting an operating loss of $7.0 million. This amount included $4.0 million of additional ...Yahoo! Finance, 1 week ago Lipocine Announces Financial and Operational Results for the First Quarter of 2016 Minyanville, 2 weeks ago
) - Innovus Pharmaceutical, Inc. (OTCQB: INNV ) and Lipocine Inc. are two specialty pharmaceutical companies focused on men and women's health that have PDUFA and ANDA dates scheduled over the next few months that could significantly alter their ...BioMedReports, 3 days ago INNOVUS PHARMACEUTICALS : Upcoming PDUFA and ANDA Approval Dates Could Catalyze Innovus Pharma (INNV) and Lipocine (LPCN) 4 Traders, 1 week ago INNOVUS PHARMACEUTICALS : May 16, 2016Upcoming PDUFA and ANDA Approval Dates Could Catalyze Innovus Pharma (INNV) and Lipocine (LPCN) 4 Traders, 1 week ago 2 Small Biotechs To Buy Before Key PDUFA Dates Seeking Alpha, 3 weeks ago
- Potential Treatment for Patients with Facial Erythema (Redness) Associated with Rosacea - - Allergan Expects PDUFA Date in First Half 2017 - DUBLIN, May 24, 2016 /PRNewswire/ -- Allergan plc (AGN) today announced that the New Drug Application ...Yahoo! Finance, 2 days ago Allergan, Inc. (AGN) Receives Good News from Japan InsiderMonkey.com, 2 days ago FDA accepts Allergan's NDA for oxymetazoline HCl cream; action date H1 2017 Seeking Alpha, 2 days ago US FDA accepts Allergan's NDA for oxymetazoline HCI cream 1.0% PharmaBiz, 23 hours ago
The FDA is continuing to review the NDA past the PDUFA goal date Sareptaannounced that theFood and Drug Administration(FDA) is continuing the pending New Drug Application (NDA) review for eteplirsen for the treatment of Duchenne muscular ...Monthly Prescribing Reference, 12 hours ago FDA to Review Topical Rosacea Treatment Monthly Prescribing Reference, 2 days ago New Hypotension Treatment Approved Pharmacy Times, 1 week ago
Source: ThinkstockSarepta Therapeutics Inc. (NASDAQ: SRPT) shares saw a handy gain on Wednesday following an analyst upgrade. Janney Montgomery Scott has a Neutral rating on Sarepta but increased its fair value estimate to $18 from $10, based on a ...24/7 Wall St, 1 day ago Sarepta Therapeutics Surges 20% On No News Benzinga.com, 6 days ago Analyst Review: Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Equilibrio Informativo, 2 weeks ago
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc. Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes. Markets are closed on certain holidays. Stock Market Holiday List By accessing this page, ...BioSpace, 3 weeks ago Sarepta volatility elevated into PDUFA date for eteplirsen Minyanville, 3 weeks ago
Novo Nordisk NVO announced that the FDA's Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) voted unanimously (16-0) in favor of the approval of IDegLira for the treatment of adults with type II diabetes. IDegLira is a once-daily, ...Zacks.com, 1 day ago
More from: , Nasdaq...and 2 other sources
The Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the US Food and Drug Administration (FDA) voted 16-0, recommending the approval of Novo Nordisk's IDegLira for the treatment of adults with type 2 diabetes. IDegLira is a ...Pharmaceutical Business Review, 1 day ago FDA Panel Unanimously Backs Novo Nordisk A/S's Diabetes Combo Drug Ideglira BioSpace, 1 day ago Novo's IDegLira receives positive vote Nordic Life Science, 1 day ago IDegLira receives unanimous 16-0 vote in favor of approval from FDA Advisory Committee PredictWallStreet, 2 days ago
on your WebpageAdd Widget >Get your members hooked!